Revive Therapeutics Announces Finalization of Amended Phase III COVID-19 Study Protocol to FDA

Revive Therapeutics Ltd. announced that it has finalized an amended protocol to the FDA for the Company’s Phase III clinical trial to evaluate the safety and efficacy of Bucillamine, an oral drug with anti-inflammatory and antiviral properties, in patients with mild to moderate COVID-19.